Welcome to our dedicated page for Coeptis Therapeutics news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics stock.
Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) combines biopharmaceutical innovation with advanced technology solutions, focusing on cell therapy platforms and AI-driven operational strategies. This page serves as the definitive source for tracking the company’s latest developments across both sectors.
Investors and industry observers will find timely updates on clinical trial progress, strategic partnerships, and technology initiatives. Key content categories include cell therapy research milestones, AI/blockchain integration updates, financial disclosures, and acquisition announcements.
Our curated news collection enables stakeholders to monitor COEP’s progress in treating cancer and autoimmune diseases while tracking its expansion into automation and decentralized technologies. Bookmark this page for streamlined access to press releases and third-party analyses that matter to your investment strategy.
Coeptis Therapeutics (NASDAQ: COEP) announced a proposed transaction to acquire assets from Deverra Therapeutics, focusing on NK cell therapies for relapsed/refractory acute myeloid leukemia (AML) and respiratory infections. The agreement grants Coeptis exclusive negotiation rights until August 31, 2023, for two IND applications and Phase 1 trials involving NK cell therapy. This acquisition aims to enhance Coeptis' R&D capabilities and diversify its portfolio by integrating a proven allogeneic platform that requires no HLA matching. With anticipated Phase 1 AML trial data expected in 2H 2023, the deal could significantly expand Coeptis' technological footprint. If completed, Deverra's CSO, Dr. Colleen Delaney, is expected to join Coeptis as Chief Scientific and Medical Officer.
FAQ
What is the current stock price of Coeptis Therapeutics (COEP)?
What is the market cap of Coeptis Therapeutics (COEP)?
